Form 4: Armata Pharmaceuticals CEO Deborah Birx Acquires Shares and Stock Options
SEC Form 4 Filing
Deborah Birx, CEO of Armata Pharmaceuticals, acquired 60,000 shares of common stock and 240,000 stock options on March 14, 2024.
Summary
- On March 14, 2024, Deborah Birx, the CEO of Armata Pharmaceuticals, acquired 60,000 shares of common stock at a price of $0.00.
- Following this transaction, Ms. Birx directly owns 260,000 shares of common stock.
- Ms. Birx also acquired 240,000 stock options with an exercise price of $3.38, expiring on March 14, 2034.
- These options vest in four equal installments of 25% on March 14th of each year from 2025 to 2028.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's acquisition of shares and options suggests confidence, but the $0 acquisition price for the shares warrants further investigation into the circumstances of the grant.
Positives
- The CEO's acquisition of shares and options could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates the CEO's recent acquisition of shares and options, which is a common form of executive compensation in the pharmaceutical industry.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry often include a mix of salary, stock options, and restricted stock units.
- Stock option vesting schedules, like the one described in the filing (25% per year over four years), are typical to incentivize long-term performance.
- Comparing the exercise price of $3.38 to the current market price of ARMP would provide further context on the potential value of these options to the CEO.
- Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- The CEO's increased stake in the company could align her interests more closely with those of shareholders.
- The vesting schedule of the stock options may incentivize the CEO to focus on long-term value creation.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of transaction: Acquisition of common stock and stock options. |
| 03/14/2025 | First vesting date for 25% of the stock options. |
| 03/14/2026 | Second vesting date for 25% of the stock options. |
| 03/14/2027 | Third vesting date for 25% of the stock options. |
| 03/14/2028 | Fourth vesting date for 25% of the stock options. |
| 03/14/2034 | Expiration date of the stock options. |
| 03/18/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.